Pfizer Inc (NYSE:PFE) agreed to donate the rights of royalties from sales of cancer drug Bavencio (avelumab) to the American Association for Cancer Research to address U.S. Federal Trade Commission concerns related to its $43-billion deal to buy Seagen Inc (NASDAQ:SGEN).

Pfizer said it received all regulatory approvals to close the deal on Thursday, about nine months after announcing the acquisition.